Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies for cancer and autoimmune diseases. Its TRACTr, TRACIr, and ARM platforms are designed to generate potent and durable immune responses while minimizing systemic safety issues.
Janux Therapeutics has dosed the first participant in a Phase 1 clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platform for autoimmune disease treatment.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07545811 |
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer |
RECRUITING | PHASE1 |
| NCT07291323 |
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. |
RECRUITING | EARLY_PHASE1 |
| NCT05783622 |
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies |
RECRUITING | PHASE1 |
| NCT05519449 |
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) |
RECRUITING | PHASE1 |
